PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-26.20%
Both yoy net incomes decline, with TRAW at -23.77%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.65%
D&A growth of 3.65% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.67%
Negative yoy SBC while TRAW is 13.46%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-515.11%
Both reduce yoy usage, with TRAW at -415.74%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.40%
Some yoy usage while TRAW is negative at -156.66%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-12704.62%
Negative yoy while TRAW is 89.30%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-57.07%
Both yoy CFO lines are negative, with TRAW at -54.71%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-196.22%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-196.22%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We slightly raise equity while TRAW is negative at -100.00%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.